Fenofibrate News and Research

RSS

Fenofibrate is a drug used to treat high levels of cholesterol and triglycerides in the blood. Fenofibrate is being studied in the treatment of advanced cancers in young patients and in the treatment of other conditions. It is a type of antilipidemic agent. Also called Lofibra and TriCor.

Simple trick supercharges T cells to fight stubborn solid tumors

Wistar researchers successfully tested a simple intervention that could unlock greater anti-tumor power in therapies that use T cells -; an approach known as "cell-based therapy," which uses specially designed T cells to fight cancer.

13 Dec 2023

Does fenofibrate improve clinical outcomes in patients with COVID-19?

Researchers assessed the effect of fenofibrate on acute COVID-19.

9 Nov 2022

Study: Fenofibrate not a useful strategy for decreasing COVID-19 severity

After showing promise in early laboratory research, the cholesterol-lowering drug fenofibrate had no significant effect on COVID-19 outcomes in a multicenter international randomized clinical trial led by Penn Medicine scientists.

8 Nov 2022

Novel drug lowers triglycerides, does not reduce cardiovascular events

Levels of triglycerides are routinely measured as part of a preventive cardiology work-up and lowering triglycerides with several classes of drugs is common medical practice.

6 Nov 2022

FDA-approved drug encourages sensory neurons to regrow after injury

A spinal cord injury damages the lines of communication between the body and brain, impeding the signals that drive movement and sensation.

18 Oct 2021

Lipid-lowering drug TriCor dramatically cuts treatment time for severe COVID-19 patients

The SARS-CoV-2 virus has infected over 165 million people worldwide causing nearly 3.5 million deaths. Recent vaccination efforts have been hindered by multiple coronavirus variants that challenge current vaccines.

23 Aug 2021

Eldelumab and Fenofibrate show potential for COVID-19

In a new study posted to the medRxiv* preprint server, researchers from the University of Pittsburgh and Barrow Neurological Institute report the results of their analysis of several RNA-Seq studies and used computational approaches to discover potential drugs against COVID-19.

10 Jun 2021

Chemical engineers devise a simpler process to incorporate hydrophobic drugs into tablets

About 60 percent of drugs on the market have hydrophobic molecules as their active ingredients. These drugs, which are not soluble in water, can be difficult to formulate into tablets because they need to be broken down into very small crystals in order to be absorbed by the human body.

8 Jun 2021

Could fenofibrate be an effective antiviral against SARS-CoV-2?

The resurgence of COVID-19 pandemic, caused by the SARS-CoV-2, has led to renewed efforts to find effective antivirals, both newly developed or repurposed drugs. A study reports the efficacy of the cholesterol-reducing drug fenofibrate in reducing infection rates of SARS-CoV-2 in cultured cells.

13 Jan 2021

Early clinical data demonstrates the efficacy of existing drug in treating COVID-19

In what has the potential to significantly change how Corona patients are being treated and the severity of the disease, research spearheaded at Jerusalem's Hebrew University gathered early clinical evidence demonstrating the efficacy of an existing drug in treating COVID-19.

22 Dec 2020

Intensive interventions in type 2 diabetes reduce risk of cardiovascular autonomic neuropathy

Intensive interventions to reduce blood glucose and blood pressure levels in type 2 diabetes reduce the risk of developing cardiovascular autonomic neuropathy (CAN), a frequent but underdiagnosed complication of diabetes that can be life-threatening.

17 Dec 2020

NTU-incubated start-up plans clinical trial of new slow-release pill for Parkinson’s disease

Materials scientists from Nanyang Technological University, Singapore (NTU Singapore) have developed a new pill which uses the stomach as a drug reservoir and delivers medicines slowly over time to patients with Parkinson's disease (PD).

16 Sep 2020

Cholesterol-lowering drugs show promise to lower COVID-19's threat

Could a simple drug, that has been on the market for decades, be used to treat COVID-19? A research team led by Hebrew University of Jerusalem (HU)'s Professor Yaakov Nahmias says that early research looks promising; their findings appear in this week's Cell Press' Sneak Peak.

15 Jul 2020

LMRI scientists discover cause of debilitating eye disease

Scientists at the Lowy Medical Research Institute have discovered one cause of a progressive, debilitating eye disease called macular telangiectasia type 2 (MacTel).

11 Sep 2019

First genetic cause for a rare eye disease discovered

John A. Moran Eye Center physician-researcher Paul S. Bernstein, MD, PhD, and his patients at the University of Utah played a key role in the recent discovery of the first genetic cause for a rare eye disease.

11 Sep 2019

TSRI chemists invent new method that simplifies late-stage modification of drug molecules

Chemists at The Scripps Research Institute have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.

27 Nov 2017

Fenofibrate drug may reduce risk of cardiovascular events in patients with type 2 diabetes

A new study shows that the drug fenofibrate might reduce the risk of cardiovascular events in patients with type 2 diabetes who have high levels of triglycerides and low levels of "good" cholesterol, despite being treated with statins.

29 Dec 2016

ACCORDION study shows lowering blood glucose can reduce progression of diabetic retinopathy

People with type 2 diabetes who intensively controlled their blood sugar level during the landmark Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial Eye Study were found to have cut their risk of diabetic retinopathy in half in a follow-up analysis conducted four years after stopping intensive therapy.

13 Jun 2016

Combining 2-DG with fenofibrate could provide non-toxic treatments for many cancers

A team of researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine recently discovered a novel, non-toxic approach to treating a wide variety of cancers.

19 May 2016

Fenofibrate benefits in diabetic retinopathy mediated through PPARα

Peroxisome proliferator–activated receptor α exerts protective effects on retinal pericytes, shows research that explains why fenofibrate is protective against diabetic retinopathy.

1 Dec 2014